Conferencias

Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial
Presenter: S. RamalingamPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: PosterBackground Benefit from combination chemotherapy extends to all age patients with advanced NSCLC Elderly patients with good performance status have comparable efficacy with 'standard' platinum-based doublets. There is concern of

Induction chemotherapy followed by concominant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell cancer: Initial analysis of a randomized phase III trial
Presenter: Everett V. VokesPresenter's Affiliation: Cancer and Leukemia Group BType of Session: ScientificBackground Induction chemotherapy has been shown to improve survival in patients with stage IIIB non-small cell lung cancer (NSCLC) compared to radiation (RT) alone Concurrent chemoradiotherapy (CT/XRT) has also been shown to be superior to

Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer
Presenter: Keunchil Park, MD, PhD Presenter's Affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea Background About 20% of all lung cancers are small cell lung cancer (SCLC) and about 1/3 of SCLC patients present with limited stage disease that is confined to the thorax

Long-Term Survival Following Immunization with BEC2 Plus BCG after Initial Therapy for Small Cell Lung Cancer
Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in advanced renal cell carcinoma (RCC). According to Dr. Négrier, despite the large number of

Increased Frequency of Radiation Therapy Treatment for Small-Cell Lung Cancer Improves Survival Rates
Lung cancer is the leading cancer killer, with more than 160,000 deaths annually. Radiation therapy is a standard treatment approach for people with lung cancer, and can be used alone or in combination with surgery or chemotherapy. In this study of radiation treatment schedules for patients with small-cell lung cancer, after five years of

NSCLC

Promising Survival in Patients with Stage III NSCLC Treated with 74 GyE Proton Therapy/Chemotherapy
Presenter: Joe Chang Presenter's Institution: University of Texas M.D. Anderson Cancer Center Background Non-Small Cell Lung Cancer (NSCLC) is a common and deadly disease, and treatment is associated with significant toxicity. Over 200,000 cases are diagnosed per year in the U.S., and over 160,000 deaths occur. For

Randomized Prospective Comparison of Adjuvant Mediastinal Radiation (RT) with or without Concurrent Chemotherapy with Cisplatin and Etoposide (PE) for Patients with Completely Resected T1-3N1-2M0 Non-Small Cell Lung Cancer (NSCLC): US
Presenter: Keller SM et al Affiliation: Beth Israel Medical Center Summary:Multiple retrospective reviews as well as the prospective study from the Lung Cancer Study Group have demonstrated a local control advantage to adjuvant radiation therapy for NSCLC. However, the overwhelming pattern of failure remains distant. This trial was initiated

Chemoradiation With or Without Surgery for Stage IIIA Non-Small Cell Lung Cancer (NSCLC): A Comparison of Survival and Patterns of Failure
Presenter: Mitchell Machtay, MD Affiliation: University of Pennsylvania Background:One of the most controversial topics in the management of NSCLC is the treatment of stage IIIA disease. Chemotherapy is generally accepted as an indicated treament in patients with good performance status. The management of local disease using surgery versus

Sequential Vs. Concurrent Chemotherapy and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (NSCLC) Analysis of Failures in a Phase III Study (RTOG 9410)
Presenter: R. Komaki, MD Affiliation: University of Texas MD Anderson Cancer Center Summary: Since the randomized trial reported by Dillman et al., the standard of care for the treatment of unresectable or inoperable non small cell lung cancer in patients with a good performance status has been sequential chemotherapy

Phase III Comparison of Sequential vs Concurrent Chemoradiation for Patients (Pts) with Unresected Stage III Non-Small Cell Lung Cancer (NSCLC): Initial Report of Radiation Therapy Oncology Group (RTOG) 9410.
Presenter: Walter Curran Affiliation: Bodine Ctr for Cancer Treatment Background: Radiation therapy with or without chemotherapy is standard therapy for locally advanced unresectable non-small cell lung cancer (NSCLC) The use of sequential cisplatin-based chemotherapy followed by thoracic radiation therapy has been shown to be